Similar pharmacokinetics and pharmacodynamics of rapid‐acting insulin lispro products <scp>SAR342434</scp> and <scp>US</scp> ‐ and <scp>EU</scp> ‐approved Humalog in subjects with type 1 diabetes

Abstract

The results of this study demonstrate similarity in insulin lispro exposure profiles and PD activity of SAR342434 solution to both US- and EU-approved Humalog, and between both US- and EU-approved Humalog, supporting the use of SAR342434 solution for injection as a follow-on product.